tirzepatide without diabetes and Cancer Risk in Individuals with and Diabetes: A Systematic Review and Meta-Analysis New Pricing, Access to Tirzepatide

En abril de 2024, el fabricante anunci mediante comunicado de prensa que SURPASS-CVOT haba alcanzado su objetivo primario, mostrando que tirzepatida no aumentaba el riesgo cardiovascular (no inferioridad) y sugiriendo posibles beneficios

The association with cyclodextrin showed several advantages such as increase in viscosity, extended release of the drug, a reduction in degradation of the drug in the antimicrobial study [37]

Modulating ROS to overcome multidrug resistance in cancer

However, it does allow for HSA reimbursement

ClinicalTrials+1 If these trials succeed, we may see GLP-1 drugs formally approved for brain-health or dementia-prevention in the coming years